Providers

Rates of sacubitril/valsartan diffusion have been slow and there has been significant geographic variation, highlighting the importance of local prescribing patterns in early drug diffusion.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, addresses major unmet needs in Fabry disease, ranging from uncontrolled pain to irreversible damage prior to treatment initiation.

Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).

This new study from Finland highlights both the potential for severe psychiatric disturbances among women with polycystic ovary syndrome (PCOS) and lack of extensive knowledge of the toll of psychoses among this group.

More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.

This commentary describes 4 dimensions of trust that have been illuminated by contributions from leading health care organizations to the ABIM Foundation’s Trust Practices Network.

The social, structural, and economic drivers of HIV are not so different from COVID-19. Still, those who have witnessed the ravages of HIV have been in a 40-year holding pattern when it comes to a vaccine, according to experts from the Rutgers School of Public Health.

A mobile app was shown to be feasible in identifying risk of obstructive sleep apnea and associated symptoms, as well as promoting management recommendations among an outpatient cohort.

Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.

President Joe Biden will provide an update today on his administration’s response to the Omicron COVID-19 variant; marked rise in lung transplants for patients with COVID-19 sparks ethical questions; an independent panel of experts will advise FDA tomorrow on the use of Merck’s COVID-19 antiviral pill.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, details various known and understudied health-related quality-of-life factors in patients with Fabry disease.

Moderate-to-severe disease, childhood onset, and systemic treatments were all associated with a greater risk of conjunctivitis in patients with atopic dermatitis, whereas use of soft and hard contact lenses were linked with risk of keratitis.

In Icelandic patients, obstructive sleep apnea were associated with a 2-fold increased risk of severe COVID-19 that required hospitalization or led to death after accounting for obesity and other comorbidities.

The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.

Daniel Wolfson, executive vice president and chief operating officer of the ABIM Foundation, speaks on factors influencing mistrust of the health care system and efforts to improve quality care.

Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.

The White House will invest $1.5 billion to bolster the nation's health care workforce; new data reveal long-term Pfizer COVID-19 vaccine efficacy in children; Idaho deactivates crisis standards of care for some portions of the state.

Discussions regarding health equity and access to care have long been implicated in breast cancer. Here, key opinion leaders discuss the latest progress in clinical trial access, digital therapeutics, and other efforts that aim to ameliorate these care gaps.

A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).

The announcement of a "strategic refresh" for payment models under the Center for Medicare and Medicaid Innovation offered no details on what practices should expect when the Oncology Care Model (OCM) expires in 2022.

Preventing addiction is key to ending the opioid epidemic—2020 alone saw more than 93,000 overdose deaths—as are expanding access to treatment, promoting recovery, and building a multifaceted strategy that incorporates nonopioid alternative and their coverage by providers. Although appropriate in certain situations, opioids are not a one-size-fits-all approach.

Daniel Greer, PharmD, BCPP, clinical assistant professor, Rutgers Ernest Mario School of Pharmacy, discusses the use of cognitive behavioral therapy (CBT) as a first-line treatment for chronic insomnia and barriers limiting its use.

Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.

Patients with nonalcoholic steatohepatitis (NASH) and obesity had a reduced risk of major adverse liver outcomes and major adverse cardiovascular (CV) events after they underwent bariatric surgery compared with patients who did not have surgery.

Patients with asthma were found to have a more than 3-fold greater risk of developing narcolepsy than those without asthma, with use of inhaled corticosteroids indicated to decrease risk.